Class information for:
Level 1: CANCER TESTIS ANTIGEN//CANCER TESTIS ANTIGENS//NY ESO 1

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
1433 2567 43.9 91%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
151 22214 IMMUNOTHERAPY//DENDRITIC CELLS//CANCER IMMUNOLOGY IMMUNOTHERAPY

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CANCER TESTIS ANTIGEN Author keyword 154 68% 5% 134
2 CANCER TESTIS ANTIGENS Author keyword 126 70% 4% 105
3 NY ESO 1 Author keyword 93 65% 3% 88
4 MAGE Author keyword 79 61% 3% 83
5 NEW YORK BRANCH Address 73 46% 5% 119
6 CELLULAR GENET UNIT Address 41 48% 2% 63
7 MAGE A Author keyword 32 85% 1% 17
8 SEREX Author keyword 29 42% 2% 54
9 MAGE 1 Author keyword 25 77% 1% 17
10 GAGE Author keyword 25 60% 1% 27

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CANCER TESTIS ANTIGEN 154 68% 5% 134 Search CANCER+TESTIS+ANTIGEN Search CANCER+TESTIS+ANTIGEN
2 CANCER TESTIS ANTIGENS 126 70% 4% 105 Search CANCER+TESTIS+ANTIGENS Search CANCER+TESTIS+ANTIGENS
3 NY ESO 1 93 65% 3% 88 Search NY+ESO+1 Search NY+ESO+1
4 MAGE 79 61% 3% 83 Search MAGE Search MAGE
5 MAGE A 32 85% 1% 17 Search MAGE+A Search MAGE+A
6 SEREX 29 42% 2% 54 Search SEREX Search SEREX
7 MAGE 1 25 77% 1% 17 Search MAGE+1 Search MAGE+1
8 GAGE 25 60% 1% 27 Search GAGE Search GAGE
9 SPERM PROTEIN 17 24 82% 1% 14 Search SPERM+PROTEIN+17 Search SPERM+PROTEIN+17
10 CANCER GERMLINE GENES 24 91% 0% 10 Search CANCER+GERMLINE+GENES Search CANCER+GERMLINE+GENES

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CANCER TESTIS ANTIGENS 304 68% 10% 264
2 CYTOLYTIC T LYMPHOCYTES 301 52% 16% 409
3 HLA A2 MELANOMAS 153 60% 6% 165
4 NY ESO 1 128 65% 5% 122
5 ANTIBODY 57B 81 96% 1% 25
6 GENE MAGE 3 81 74% 2% 60
7 HUMAN GENE MAGE 3 79 74% 2% 58
8 MAGE GENES 76 88% 1% 36
9 HUMAN MELANOMA 57 18% 11% 293
10 MAGE FAMILY 55 87% 1% 27

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Cancer/testis (CT) antigens: Potential targets for immunotherapy 2009 220 81 81%
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy 2014 42 171 56%
Cancer/testis antigens, gametogenesis and cancer 2005 612 94 60%
Human T cell responses against melanoma 2006 359 189 57%
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy 2002 411 88 76%
Cancer/Testis Antigens Trigger Epithelial-Mesenchymal Transition and Genesis of Cancer Stem-Like Cells 2015 1 109 57%
A listing of human tumor antigens recognized by T cells: March 2004 update 2005 266 211 58%
A listing of human tumor antigens recognized by T cells 2001 310 142 68%
The biology of cancer testis antigens: Putative function, regulation and therapeutic potential 2011 38 178 74%
Tumor-specific shared antigenic peptides recognized by human T cells 2002 238 108 69%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 NEW YORK BRANCH 73 46% 4.6% 119
2 CELLULAR GENET UNIT 41 48% 2.5% 63
3 CLIN ONCOIMMUNOL 20 36% 1.7% 44
4 SURG BRANCH 18 13% 5.0% 128
5 LAUSANNE BRANCH 17 19% 3.1% 79
6 HUMAN IMMUNE THER Y 16 58% 0.7% 19
7 LUDWIG CLIN TRIAL 15 73% 0.4% 11
8 BRUSSELS BRANCH 14 23% 2.1% 54
9 BIOTHER Y STEM CELL TRANSPLANT PROGRAM 10 73% 0.3% 8
10 OFF CLIN TRIALS MANAGEMENT 8 100% 0.2% 5

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000226476 CANC VACCINE DEV//INNOVAT CANC THER Y//PERSONALIZED PEPTIDE VACCINE
2 0.0000180063 5T4//TUMOR IMMUNOL BIOL//5T4 ONCOFETAL ANTIGEN
3 0.0000176996 NECDIN//REGULAT MACROMOL FUNCT//REGULAT NEURONAL DEV
4 0.0000166067 BELAGENPUMATUCEL L//SRL172//PA MSHA
5 0.0000147082 CANC VACCINE DEV PROGRAM//CANC SECT//ONCOANTIGENS
6 0.0000133867 CCDC134//TUMOR IMMUN TOLERANCE SECT//ANTIGEN SPECIFIC CTL FUNCTION
7 0.0000108447 TUMOR INFILTRATING LYMPHOCYTES//ADOPTIVE IMMUNOTHERAPY//AUTOLYMPHOCYTE THERAPY
8 0.0000105290 PRAME//LEUKEMIA ASSOCIATED ANTIGENS//UNIT 900
9 0.0000092686 DENDRITIC CELLS//DENDRITIC CELL//TUMOR LYSATE
10 0.0000091580 CHIMERIC ANTIGEN RECEPTOR//ADOPTIVE CELL THERAPY//CHIMERIC IMMUNE RECEPTOR